Abstract
A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have